Alzheimer's disease start up Neurotrope BioSciences is to proceed to Phase IIb studies of its lead product bryostatin after positive top-line safety data from a Phase IIa trial.
The product acts by modulating protein kinase C epsilon (PKCe), activation of which, the company says, has been shown to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?